Literature DB >> 1929314

Pharmacokinetics of single-dose intravenous, oral, and intraperitoneal pefloxacin in patients on chronic ambulatory peritoneal dialysis.

J L Schmit1, L Hary, P Bou, H Renaud, P F Westeel, M Andrejak, A Fournier.   

Abstract

Comparison of plasma and dialysate concentrations of pefloxacin after intravenous, oral, or intraperitoneal administration shows excellent bidirectional diffusion of the quinolone through the peritoneal membrane, demonstrating that therapeutical concentrations can be achieved in the dialysate after intravenous or oral administration. In this study, the half-life of the drug was 18.8 +/- 1.4 h, i.e., apparently longer than that reported for normal controls or uremic patients on hemodialysis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1929314      PMCID: PMC245198          DOI: 10.1128/AAC.35.7.1492

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.

Authors:  E Singlas; A Leroy; E Sultan; M Godin; B Moulin; A M Taburet; M Dhib; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

2.  Reduced enteral absorption of ciprofloxacin in the presence of antacids.

Authors:  G Höffken; K Borner; P D Glatzel; P Koeppe; H Lode
Journal:  Eur J Clin Microbiol       Date:  1985-06       Impact factor: 3.267

3.  Improved high-performance liquid chromatographic determination of pefloxacin and its metabolite norfloxacin in human plasma and tissue.

Authors:  G Montay; J P Tassel
Journal:  J Chromatogr       Date:  1985-04-12

Review 4.  Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  T W Paton; W R Cornish; M A Manuel; B G Hardy
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

5.  Peritonitis in continuous ambulatory peritoneal dialysis. Laboratory and clinical studies.

Authors:  R Gokal; J M Ramos; D M Francis; R E Ferner; T H Goodship; G Proud; A J Bint; M K Ward; D N Kerr
Journal:  Lancet       Date:  1982-12-18       Impact factor: 79.321

6.  Pharmacokinetics of pefloxacin in renal insufficiency.

Authors:  G Montay; C Jacquot; J Bariety; R Cunci
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.

Authors:  G Montay; Y Goueffon; F Roquet
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

8.  Cefotaxime and desacetyl cefotaxime kinetics in renal impairment.

Authors:  G R Matzke; P A Abraham; C E Halstenson; W F Keane
Journal:  Clin Pharmacol Ther       Date:  1985-07       Impact factor: 6.875

9.  Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers.

Authors:  A M Frydman; Y Le Roux; M A Lefebvre; F Djebbar; J B Fourtillan; J Gaillot
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

10.  The comparative in-vitro activity of pefloxacin.

Authors:  A King; I Phillips
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

View more
  2 in total

Review 1.  Clinical pharmacokinetics during continuous ambulatory peritoneal dialysis.

Authors:  C A Taylor; E Abdel-Rahman; S W Zimmerman; C A Johnson
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 2.  Pefloxacin clinical pharmacokinetics.

Authors:  F Bressolle; F Gonçalves; A Gouby; M Galtier
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.